Applying quality by design principles in the development and preparation of a new radiopharmaceutical: Technetium-99m-imatinib mesylate

Basit Öğe Kaydı
dc.contributor.authorGündoğdu, Evren
dc.contributor.authorDemir, Emine Selin
dc.contributor.authorÖzgenç, Emre
dc.contributor.authorYeğen, Gizem
dc.contributor.authorAksu, Buket
dc.date.accessioned2021-05-15T11:33:45Z
dc.date.available2021-05-15T11:33:45Z
dc.date.issued2020
dc.departmentEczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalıen_US
dc.descriptionAksu, Buket/0000-0001-7555-0603; gundogdu, evren/0000-0003-2111-101X; Yegen, Gizem/0000-0003-0427-8918
dc.description.abstractThe clinical impact and accessibility of Tc-99m tracers for cancer diagnosis would be greatly enhanced by the availability of a new, simple, and easy labeling process and radiopharmaceuticals. In this study, Technetium-99m-imatinib mesylate ([Tc-99m]TcIMT) was developed and prepared as a new radiopharmaceutical for breast cancer diagnosis. The effect of critical process parameters on the product quality and stability of [Tc-99m]TcIMT was investigated using the quality by design concept of the ICH Q8 (Pharmaceutical Development) guideline. [Tc-99m]TcIMT was subjected to in vitro cell binding studies to determine healthy and cancer cell affinity using HaCaT and MCF-7 cells, respectively. The optimal radiolabeling procedure with 1 mg of IMT, 500 mu g of stannous chloride, 0.1 mg of ascorbic acid, and (1m)Ci Tc-99m radioactivity was obtained for [Tc-99m]TcIMT. The pH of the reaction mixture was adjusted to 10 and allowed to react for 15 min at room temperature. The radiochemical purity of [Tc-99m]TcIMT was found to be higher than 90% at room temperature up to 6 h. Chromatography analysis revealed >85% [Tc-99m]Tc1MT complex formation with promising stability in saline, cell medium, and serum up to 6 h. The radiolabeled complex showed a higher cell-binding ratio to MCF-7 cells (88.90% +/- 3.12) than HaCaT cells (45.64 +/- 4.72) when compared to Tc-99m. Our findings show that the developed preparation method for [Tc-99m]TcIMT falls well within the proven acceptable ranges. Applying quality by design (QbD) principles is feasible and worthwhile for the preparation of [Tc-99m]TcIMT. In conclusion, radiochemical purity, stability, and in vitro cell binding evaluation of the [Tc-99m]TCIMT complex indicate that the agent can be utilized for imaging of breast cancer cells.en_US
dc.description.sponsorshipT.R. Prime Ministry State Planning Organization FoundationTurkiye Cumhuriyeti Kalkinma Bakanligi [09/DPT/001]; COST (European Cooperation in Science and Technology) ActionEuropean Cooperation in Science and Technology (COST) [CA17104]en_US
dc.description.sponsorshipThe authors would like to thank the T.R. Prime Ministry State Planning Organization Foundation (project number: 09/DPT/001). The authors would like to thank the COST (European Cooperation in Science and Technology) Action (project number: CA17104). The authors would like to acknowledge the support of Ege University Nuclear Medicine Department in obtaining the <SUP>99m</SUP>Tc radionuclide.en_US
dc.identifier.doi10.1021/acsomega.9b04327
dc.identifier.endpage5305en_US
dc.identifier.issn2470-1343
dc.identifier.issue10en_US
dc.identifier.pmid32201818
dc.identifier.scopus2-s2.0-85081547090
dc.identifier.scopusqualityQ1
dc.identifier.startpage5297en_US
dc.identifier.urihttps://doi.org/10.1021/acsomega.9b04327
dc.identifier.urihttps://hdl.handle.net/20.500.12939/223
dc.identifier.volume5en_US
dc.identifier.wosWOS:000520853400064
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYeğen, Gizem
dc.institutionauthorAksu, Buket
dc.language.isoen
dc.publisherAmer Chemical Socen_US
dc.relation.ispartofAcs Omega
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDevelopmenten_US
dc.subjectTechnetium-99m-Imatinib Mesylateen_US
dc.subjectRadiopharmaceuticalen_US
dc.titleApplying quality by design principles in the development and preparation of a new radiopharmaceutical: Technetium-99m-imatinib mesylate
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical Technetium-99m-Imatinib Mesylate .pdf
Boyut:
2.72 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/ Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu